NCT07323394Not yet recruiting
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 22 Dec 2025
- Start date
- Jan 2026
- Primary completion date
- Jun 2026
- Lead sponsor
- PeriPharm
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07323394
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jan 2026 to the primary completion date, Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
Other
- Caregivers whose child has been diagnosed with severe atopic dermatitis ;
- Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
- Other parent or caregiver within the household of the child with atopic dermatitis.
Who the study is looking for
- Aged ≥18 years;
- Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
- Able to read and understand French or English;
- Willing and able to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.